A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 16, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions

Phenylketonuria (PKU)

Interventions

DRUG

JNT-517 Tablet

JNT-517: 75 mg BID

OTHER

Placebo

Placebo Tablet: BID

DRUG

JNT-517 Tablet

JNT-517: 150 mg BID

Trial Locations (1)

RECRUITING

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT06637514 - A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria | Biotech Hunter | Biotech Hunter